Home › Blood Cancers › Texas › Houston
Blood Cancers clinical trials in Houston, TX
46 studies for Blood Cancers are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
CD70.CAR for AML and Other CD70+ Leukemias
RecruitingPhase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RecruitingPhase 3
- University of Texas MD Anderson Cancer Center ( Site 0007), Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- UT MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of Texas, Houston
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- UT MD Anderson Cancer Center, Houston
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center - University of Texas, Houston
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- The University of Texas MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Texas Children's Hospital, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
- The University of TX MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- Md Anderson Cancer Center, Houston
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
RecruitingObservational study
- M D Anderson Cancer Center, Houston
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RecruitingPhase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
RecruitingEarly phase 1
- M D Anderson Cancer Center, Houston
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
RecruitingObservational study
- UT MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
RecruitingPhase 2Healthy volunteers welcome
- M D Anderson Cancer Center, Houston
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Recruiting
- M D Anderson Cancer Center, Houston
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RecruitingPhase 1
- M D Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- MD Anderson, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RecruitingPhase 1/2
- M D Anderson Cancer Center, Houston
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
RecruitingEarly phase 1
- M D Anderson Cancer Center, Houston
Expressive Writing for the Management of Stress in Cancer Survivors
Recruiting
- M D Anderson Cancer Center, Houston
The Impact of COVID-19 on Pulmonary Procedures
RecruitingObservational studyHealthy volunteers welcome
- M D Anderson Cancer Center, Houston
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
RecruitingObservational study
- M D Anderson Cancer Center, Houston
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RecruitingPhase 2
- University of Texas MD Anderson MD Anderson Cancer Center, Houston
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
Improving Comprehensive Care of Cancer Patients
RecruitingHealthy volunteers welcome
- Baylor College of Medicine, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
RecruitingObservational studyHealthy volunteers welcome
- M D Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RecruitingPhase 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Blood Cancers trials in other cities
- Boston, MA28 studies
- New York City, NY26 studies
- Washington, DC19 studies
- Seattle, WA18 studies
- Baltimore, MD18 studies
- Los Angeles, CA18 studies
- Durham, NC16 studies
- Chicago, IL16 studies
- Edison, NJ14 studies
- Columbus, OH14 studies
- Philadelphia, PA14 studies
- Nashville, TN13 studies
Other studies in Houston
- Non-Small Cell Lung Cancer143 studies
- Breast Cancer126 studies
- Cancer (all types)124 studies
- Colorectal Cancer101 studies
- Metastatic Cancer100 studies
- Ovarian Cancer90 studies
- Acute Myeloid Leukemia88 studies
- Lung Cancer78 studies
- Prostate Cancer73 studies
- Endometrial Cancer69 studies
- Melanoma61 studies
- Pancreatic Cancer59 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.